Selected articles
Articles for label Svatoň Martin are displayed.. Show all articles
Diagnosis of lung cancer
05/2020 MUDr. Martin Svatoň, Ph.D.
The aim of this article is to get a basic idea of the modern trend in the diagnosis of lung cancer. The article deals briefly with the overall view of the patient, as well as imaging methods and verification of found lesions. In the field of imaging methods, this article clarifies the concept of using PET/CT (positron emission tomography / computed tomography) of the trunk and MR (magnetic resonance) of the brain. In morphological verification, the article deals with both classical methods and modern navigation bronchoscopic systems. Pathological requirements for adequate diagnosis of lung cancer, including molecular markers, are also included.
ENTIRE ARTICLE
The aim of this article is to get a basic idea of the modern trend in the diagnosis of lung cancer. The article deals briefly with the overall view of the patient, as well as imaging methods and verification of found lesions. In the field of imaging methods, this article clarifies the concept of using PET/CT (positron emission tomography / computed tomography) of the trunk and MR (magnetic resonance) of the brain. In morphological verification, the article deals with both classical methods and modern navigation bronchoscopic systems. Pathological requirements for adequate diagnosis of lung cancer, including molecular markers, are also included.
Crizotinib – still „gold standard“ for patients with pulmonary adenocarcinoma with ALK translocation?
06/2017 MUDr. Martin Svatoň, prof. MUDr. Miloš Pešek, CSc.
Crizotinib is a tyrosine kinase inhibitor targeting ALK translocation. Based on Profile 1007 and Profile 1014 trial, it has become the basis of treatment for patients with ALK translocation in the first as well as the second line of treatment. Its toxic profile is acceptable and usually well manageable. In the Czech Republic, due to the form of payment, it has been used exclusively in the second line, where we document the experience from our workplace with this drug. Currently, other drugs (ceritinib, alectinib) have proven to be effective in patients with ALK translocations, when it is a question of choosing a treatment plan, which is discussed in more detail in the discussion.
ENTIRE ARTICLE
Crizotinib is a tyrosine kinase inhibitor targeting ALK translocation. Based on Profile 1007 and Profile 1014 trial, it has become the basis of treatment for patients with ALK translocation in the first as well as the second line of treatment. Its toxic profile is acceptable and usually well manageable. In the Czech Republic, due to the form of payment, it has been used exclusively in the second line, where we document the experience from our workplace with this drug. Currently, other drugs (ceritinib, alectinib) have proven to be effective in patients with ALK translocations, when it is a question of choosing a treatment plan, which is discussed in more detail in the discussion.